Drug Trial Radar · NCT07024212
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Jun 18, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts. The primary objective of Part 1 is to assess the preliminary efficacy of DR10624 Injection in MASLD subjects at high risk of liver fibrosis. The secondary objectives are to assess the safety and tolerability, PK profiles, and immunogenicity of DR10624 Injection in these subjects. The exploratory objectives are to assess the efficacy of DR10624 Injection in these subjects using LSM assessed by MRE, and its impact on Lp(a) and body composition.The primary objective of Part 2 is to assess the safety and tolerability of DR10624 Injection in MetALD subjects at high risk of liver fibrosis. This clinical trial is currently only conducting Part 1 of the study.
Conditions
- MASLD
Interventions
DR10624 InjectionDrug
Drug: DR10624 injection
PlaceboDrug
Drug: Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes of LFCTime frame: From baseline to Week 12
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, China
Nanjing Gulou Hospital
Nanjing, China
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.